Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. A Phase Ib Study.

NCT03085225 is registered in ClinicalTrials.gov with Institut Bergonié as lead sponsor.

NCT NCT03085225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03085225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. A Phase Ib Study.
Lead sponsor
Institut Bergonié
Phase
Phase 1
Overall status
Completed
Start date
May 5, 2017
Completion date
January 4, 2022
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian carcinoma, soft tissue sarcoma